Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Total Lease Liabilities under IFRS 16 by Year
Total Lease Liabilities under IFRS 16 ($M)
Novartis Total Lease Liabilities under IFRS 16: $1,920M in FY2025, up 6.5% from a year earlier.
Latest, FY2025
1,920
Period ended Dec 31, 2025
Change on a year earlier
+6.5%
1,803 in FY2024
History
7 years
Since FY2019
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F Note 10.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Lease Liabilities under IFRS 16 ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,920 | +6.5% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 1,803 | -1.4% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2023 | Dec 31, 2023 | 1,828 | +2.2% | Novartis Form 20-F (0001370368-25-000004) ↗ |
| FY2022 | Dec 31, 2022 | 1,789 | -5.6% | Novartis Form 20-F (0001370368-24-000004) ↗ |
| FY2021 | Dec 31, 2021 | 1,896 | -5.4% | Novartis Form 20-F/A (0001370368-23-000048) ↗ |
| FY2020 | Dec 31, 2020 | 2,005 | +2.9% | Novartis Form 20-F (0001370368-22-000010) ↗ |
| FY2019 | Dec 31, 2019 | 1,949 | – | Novartis Form 20-F (0001370368-21-000006) ↗ |
Cite this data
StockData. (2026). Novartis Total Lease Liabilities under IFRS 16 ($M), annual FY2019–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/ops-lease-liab-total
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.